775K shares changed hands in the last trading session. Trading volume was down 87.27% under the stocks average daily volume.
Investors are more bearish of late as indicated by the uptick in short interest. The firm saw a rise in short interest from September 29, 2017 to October 13, 2017 of 88.90%. Short shares grew 683,991 over that period. With short interest at 1,453,427 and short average daily volume at 16,331,885, days to cover is 0.0 and the percentage of shorted shares is 0.22% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (CLSN). As of the end of the quarter Bank Of America Corp /de/ had acquired a total of 5,946 shares growing its position 243.3%. The value in dollars increased from $1,000 to $2,000 a change of 100.0% since the last quarter. As of quarter end Susquehanna International Group, Llp had sold 543 shares trimming its stake by 4.9%. The value of the investment in (CLSN) went from $14,000 to $3,000 decreasing 78.6% quarter to quarter.
As of quarter end Jane Street Group, LLC had bought a total of 122,931 shares growing its holdings by 667.6%. The value of the investment in Celsion Corporation went from $22,000 to $41,000 a change of $19,000 for the reporting period. As of the end of the quarter Morgan Stanley had sold 29 shares trimming its stake by 0.5%. The value of the total investment in Celsion Corporation decreased from $2,000 to $2,000 decreasing 0.0% quarter over quarter.
On October 5 the company was upgraded from “Buy” to “Buy” by Maxim Group.
In the market the company is trading down by 3.98% percent from yesterday’s close. Shares are trading at $2.17 which is significantly below $2.83, the stock’s 50 day moving average and quite a bit higher than the 200 day moving average of $1.80. The 50 day moving average was down $-0.66 and the 200 day average went up by +20.65%.
In the latest earnings report the EPS was $-5.58 and is projected to be $-3.50 for the current year with 8,351,000 shares now outstanding. Next quarter’s EPS is estimated at $-0.39 with next year’s EPS projected to be $-1.17.
Celsion Corporation (Celsion), launched on May 17, 2000, is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, deoxyribonucleic acid (DNA)-mediated immunotherapy and ribonucleic acid (RNA)-based therapies. Its product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA mediated immunotherapy for the localized treatment of ovarian and brain cancers. The Company has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer RNA..